Table 1 Correlation between ZNF529-AS1 expression and clinicopathological characteristics in HCC
Characteristic | Low expression of ZNF529-AS1 | High expression of ZNF529-AS1 | p |
|---|---|---|---|
n | 187 | 187 | Â |
T stage, n (%) |  |  | < 0.001 |
 T1 | 111 (29.9%) | 72 (19.4%) |  |
 T2 | 35 (9.4%) | 60 (16.2%) |  |
 T3 | 32 (8.6%) | 48 (12.9%) |  |
 T4 | 7 (1.9%) | 6 (1.6%) |  |
N stage, n (%) | Â | Â | 0.364 |
 N0 | 130 (50.4%) | 124 (48.1%) |  |
 N1 | 1 (0.4%) | 3 (1.2%) |  |
M stage, n (%) | Â | Â | 1.000 |
 M0 | 130 (47.8%) | 138 (50.7%) |  |
 M1 | 2 (0.7%) | 2 (0.7%) |  |
Pathologic stage, n (%) |  |  | < 0.001 |
 Stage I | 104 (29.7%) | 69 (19.7%) |  |
 Stage II | 33 (9.4%) | 54 (15.4%) |  |
 Stage III | 34 (9.7%) | 51 (14.6%) |  |
 Stage IV | 3 (0.9%) | 2 (0.6%) |  |
Tumor status, n (%) | Â | Â | 0.078 |
 Tumor free | 110 (31%) | 92 (25.9%) |  |
 With tumor | 68 (19.2%) | 85 (23.9%) |  |
Gender, n (%) | Â | Â | 0.047 |
 Female | 51 (13.6%) | 70 (18.7%) |  |
 Male | 136 (36.4%) | 117 (31.3%) |  |
Race, n (%) | Â | Â | 0.942 |
 Asian | 78 (21.5%) | 82 (22.7%) |  |
 Black or African American | 9 (2.5%) | 8 (2.2%) |  |
 White | 92 (25.4%) | 93 (25.7%) |  |
Age, n (%) | Â | Â | 0.055 |
 ≤ 60 | 79 (21.2%) | 98 (26.3%) |  |
 > 60 | 108 (29%) | 88 (23.6%) |  |
Weight, n (%) | Â | Â | 0.100 |
 ≤ 70 | 86 (24.9%) | 98 (28.3%) |  |
 > 70 | 91 (26.3%) | 71 (20.5%) |  |
Height, n (%) | Â | Â | 0.525 |
 < 170 | 98 (28.7%) | 103 (30.2%) |  |
 ≥ 170 | 74 (21.7%) | 66 (19.4%) |  |
BMI, n (%) | Â | Â | 0.347 |
 ≤ 25 | 85 (25.2%) | 92 (27.3%) |  |
 > 25 | 86 (25.5%) | 74 (22%) |  |
Residual tumor, n (%) | Â | Â | 1.000 |
 R0 | 164 (47.5%) | 163 (47.2%) |  |
 R1 | 8 (2.3%) | 9 (2.6%) |  |
 R2 | 1 (0.3%) | 0 (0%) |  |
Histologic grade, n (%) |  |  | < 0.001 |
 G1 | 39 (10.6%) | 16 (4.3%) |  |
 G2 | 100 (27.1%) | 78 (21.1%) |  |
 G3 | 45 (12.2%) | 79 (21.4%) |  |
 G4 | 2 (0.5%) | 10 (2.7%) |  |
Adjacent hepatic tissue inflammation, n (%) | Â | Â | 0.049 |
 None | 62 (26.2%) | 56 (23.6%) |  |
 Mild | 47 (19.8%) | 54 (22.8%) |  |
 Severe | 14 (5.9%) | 4 (1.7%) |  |
AFP (ng/ml), n (%) |  |  | < 0.001 |
 ≤ 400 | 129 (46.1%) | 86 (30.7%) |  |
 > 400 | 17 (6.1%) | 48 (17.1%) |  |
Albumin (g/dl), n (%) | Â | Â | 1.000 |
 < 3.5 | 37 (12.3%) | 32 (10.7%) |  |
 ≥ 3.5 | 123 (41%) | 108 (36%) |  |
Prothrombin time, n (%) | Â | Â | 0.455 |
 ≤ 4 | 112 (37.7%) | 96 (32.3%) |  |
 > 4 | 43 (14.5%) | 46 (15.5%) |  |
Child–Pugh grade, n (%) |  |  | 0.001 |
 A | 123 (51%) | 96 (39.8%) |  |
 B | 4 (1.7%) | 17 (7.1%) |  |
 C | 1 (0.4%) | 0 (0%) |  |
Fibrosis ishak score, n (%) | Â | Â | 0.551 |
 0 | 38 (17.7%) | 37 (17.2%) |  |
 1/2 | 18 (8.4%) | 13 (6%) |  |
 3/4 | 12 (5.6%) | 16 (7.4%) |  |
 5/6 | 46 (21.4%) | 35 (16.3%) |  |
Vascular invasion, n (%) | Â | Â | 0.001 |
 No | 119 (37.4%) | 89 (28%) |  |
 Yes | 41 (12.9%) | 69 (21.7%) |  |
Age, median (IQR) | 64 (55, 69) | 59.5 (50, 67) | 0.004 |